Perinatal Hepatitis B Prevention Program - Auxiliary Prevention Projects

The summary for the Perinatal Hepatitis B Prevention Program - Auxiliary Prevention Projects grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control and Prevention, which is the U.S. government agency offering this grant.
Perinatal Hepatitis B Prevention Program - Auxiliary Prevention Projects:










i. Purpose: The purpose of these activities is to support the goals of the HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, 2014-2016 (available at http://aids.gov/pdf/viral-hepatitis-action-plan.pdf) by ensuring Hepatitis B-infected pregnant women are identified so that their infants can receive timely post-exposure prophylaxis, improvements in post-vaccination serologic testing to improve efficiencies, and data collection to assess infant outcomes




ii. Outcomes: Increased identification of Hepatitis B-infected pregnant women; increased rates of post-vaccination serologic testing among infants born to Hepatitis B-infected pregnant women; and assessment of factors associated with infant outcomes




iii. Strategies and Activities:




Collaborations: To maximize opportunities for Hepatitis B prevention through vaccination, referral for care, and treatment of persons found to have chronic Hepatitis B infection, this FOA encourages Perinatal Hepatitis B Prevention Program collaborations and service integration as a program imperative of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Such collaborations can increase efficiency, reduce redundancy, eliminate missed opportunities, and improve outcomes through the use of shared data and services.

a. With CDC-funded programs: Applicants should create and build upon internal health department collaborations to improve identification of Hepatitis B-infected pregnant women; screen their household and sexual contacts for Hepatitis B and complete vaccination of susceptible persons; refer persons with chronic Hepatitis B infection for care and treatment; and report infants, household, and sexual contacts with chronic Hepatitis B infection to the National Notifiable Diseases Surveillance System.
b. With organizations external to CDC: Opportunities for collaboration with non-CDC organizations will be encouraged; non-CDC organizations may include commercial laboratories and health systems, other federal agencies, non-profit organizations, and professional societies.



2. Target Populations: Target populations shall represent a diversity of Hepatitis B-infected pregnant women with regards to race, ethnicity, and country of birth (i.e., U.S.-born versus foreign-born).


1.a. Inclusion: N/A









iv. Funding Strategy: N/A




b. Evaluation and Performance Measurement:




i. CDC Evaluation and Performance Measurement Strategy: The proportion of Hepatitis B-infected pregnant women identified (compared to estimated), compared to prior years based on data submitted by Perinatal Hepatitis B Prevention Programs; the proportion of infants receiving timely post-vaccination serologic testing (by 12 and 18 months of age), compared to prior years, and identification of barriers to post-vaccination serologic testing to help model best practices; demographic and clinical factors (both maternal and infant) associated with infant outcomes (awardees will collect and manage data and submit to CDC for analysis).
ii. Applicant Evaluation and Performance Measurement Plan: Applicants shall describe procedures planned or currently used to carry out and monitor the performance of these activities, including but not limited to tracking progress, reporting, and data collection.







c. Organizational Capacity of Awardees to Execute the Approach: Applicants shall describe the anticipated level of organizational capacity needed to implement the award. Organizational capacity includes skill sets such as program planning, program evaluation, performance monitoring, financial reporting, budget management and administration, and personnel management. Applicants shall describe prior and current collaborative efforts with commercial laboratories to improve the identification of Hepatitis B-infected pregnant women. Applicants should demonstrate relevant experience and capacity (management, administrative, and technical) to implement the activities and achieve the project outcomes, experience and capacity to implement the evaluation plan, and a staffing plan and project management structure sufficient to achieve the project outcomes and which clearly define staff roles. Applicants must also be fully capable of managing the required procurement efforts, including the ability to write and award contracts in accordance with applicable regulations.




d. Work Plan: Applicants should provide a high-level work plan that covers the duration of the project, with more detail for Fiscal Year 2016. Applicants should clearly describe how the components in the work plan crosswalk to the strategies and activities and outcomes presented in the logic model and narrative sections of the FOA. The work plan is not a separate, stand alone document.




e. CDC Monitoring and Accountability Approach: Monitoring activities include routine and ongoing communication between CDC and awardees, site visits, and awardee reporting (including work plans, performance, and financial reporting). Consistent with applicable grants regulations and policies, CDC expects the following to be included in post-award monitoring for grants and cooperative agreements:


Tracking awardee progress in achieving the desired outcomes.
Ensuring the adequacy of awardee systems that underlie and generate data reports.
Creating an environment that fosters integrity in program performance and results.


Monitoring may also include the following activities:

Ensuring that work plans are feasible based on the budget and consistent with the intent of the award.
Ensuring that awardees are performing at a sufficient level to achieve outcomes within stated timeframes.
Working with awardees on adjusting the work plan based on achievement of outcomes, evaluation results, and changing budgets.
Monitoring performance measures (both programmatic and financial) to assure satisfactory performance levels.


Other activities deemed necessary to monitor the award, if applicable.

These activities may include monitoring and reporting activities that assist grants management staff (e.g., grants management officers and specialists, and project officers) in the identification, notification, and management of high-risk grantees.




f. CDC Program Support to Awardees: CDC and awardees share responsibility for successful implementation of the award and meeting the identified outcomes. CDC will have substantial involvement with this FOA, referring to federal programmatic collaboration or participation that the awardee can expect in implementing the award. Frequent conference calls will be scheduled to assure milestones are met on time and appropriately. CDC will provide technical assistance in the form of commitment of personnel with subject matter expertise in perinatal Hepatitis B and epidemiology/public health. CDC will facilitate information sharing between awardees and subject matter experts through conference calls and other avenues to be determined. CDC will perform analyses on data submitted by awardees.











CDC-RFA-PS16-1602 Logic Model: Perinatal Hepatitis B Prevention Program - Auxiliary Prevention Projects




Strategies and Activities


Short-Term Outcomes


Long-Term Outcomes




Strategy: Increase identification of Hepatitis B-infected pregnant women
Activity #1: Capture-recapture analysis, e.g., review of commercial laboratory testing results for pregnant women, metabolic screening data, immunization registries, etc. to increase identification of infants born to Hepatitis B-infected women for case management and prophylaxis
Activity #2: Training providers of women/infants who were not reported prenatally to the Perinatal Hepatitis B Prevention Program of importance of reporting and case management/prophylaxis



Narrowing the gap between the expected and identified number of Hepatitis B- infected pregnant women, resulting in an increase in proportion of infants receiving case management and post-exposure prophylaxis


Reduction in perinatal Hepatitis B infections with subsequent reduction in early deaths due to cirrhosis or liver cancer




Strategy: Improve proportion of case-managed infants receiving post-vaccination serologic testing
Activity #1: Enhanced tracking and follow-up procedures of case-managed infants to improve proportion receiving post-vaccination serologic testing, prioritizing infants born to mothers who are Hepatitis B e antigen positive or who have viral loads greater than or equal to 106 copies/mL when these laboratory results are available
Activity #2: Identify barriers to post-vaccination serologic testing to help model best practices



Increasing rates of post-vaccination serologic testing among case-managed infants, resulting in increased revaccination of nonresponding infants and improved identification and linkage to care for infected infants


Reduction in horizontal transmission of Hepatitis B infection with subsequent reduction in early deaths due to cirrhosis or liver cancer;
facilitation of medical follow-up for perinatally-infected infants




Strategy: Ascertain demographic and clinical factors associated with perinatal Hepatitis B transmission and vaccine response
Activity #1: Collect and report data on mothers and infants, including data regarding maternal antiviral therapy, for analysis



Ascertainment of factors associated with Hepatitis B transmission and vaccine response


Ascertainment of factors associated with Hepatitis B transmission and vaccine response










Federal Grant Title: Perinatal Hepatitis B Prevention Program - Auxiliary Prevention Projects
Federal Agency Name: Centers for Disease Control and Prevention
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: CDC-RFA-PS16-1602
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.270
CFDA Descriptions: Adult Viral Hepatitis Prevention and Control
Current Application Deadline: Jun 15, 2015 Electronically submitted application
Original Application Deadline: Jun 15, 2015 Electronically submitted application
Posted Date: Apr 16, 2015
Creation Date: Apr 16, 2015
Archive Date: Jul 15, 2015
Total Program Funding: $1,200,000
Maximum Federal Grant Award: $120,000
Minimum Federal Grant Award: $40,000
Expected Number of Awards: 5
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Special district governments
County governments
City or township governments
State governments
Additional Information on Eligibility

Eligible Applicants are: The current 64 grantees with established Perinatal Hepatitis B Prevention Programs (PHBPPs) that are funded through CDC-RFA-IP13-1301, which are the 50 state health departments or their bona fide agents, the District of Columbia, New York City, Philadelphia, Houston, Chicago, and San Antonio, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.

Eligibility is limited to those jurisdictions with existing PHBPPs, as it is only possible to carry out the activities of the FOA with existing PHBPPs. Through grants to public health immunization programs, CDC created the U.S. PHBPP in 1990 to accelerate progress toward the elimination of perinatal Hepatitis B virus transmission. The current 64 grantees with established PHBPPs are funded through CDC-RFA-IP13-1301, which are the 50 state health departments or their bona fide agents, the District of Columbia, New York City, Philadelphia, Houston, Chicago, and San Antonio, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. PHBPPs identify pregnant Hepatitis B-infected pregnant women (as determined by Hepatitis B surface antigen-positive [HBsAg]) and ensure their infants receive timely immunoprophylaxis and post-vaccination serologic testing.


Link to Full Grant Announcement
Grant Announcement Contact
Sarah Schillie ggi1@cdc.gov
Grants Policy

Centers for Disease Control and Prevention 770-488-2756
Similar Government Grants
Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments
Improving Hepatitis B and C Care Cascades: Focus on Increased Testing and Diagnosis
Cohort Study to Assess Population Impact of Current and Evolving Chronic Viral Hepatitis T...
Centers for Disease Control and Prevention Natural History and Prevention of Viral Hepatit...
Opportunity PA-11-033
Viral Hepatitis Surveillance
Viral Hepatitis - Prevention and Surveillance
More Grants from the Centers for Disease Control and Prevention
93.067
Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities o...
Technical Assistance to Support Comprehensive Combination HIV Prevention, Care and Treatme...
Strengthening Ebola rapid detection and response capacity through community based surveill...
test2

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com